---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-159062"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:47:06.791920+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Corbus Pharma amends employment agreements: CEO salary $673,625, CFO salary $501,273

## Summary
- New employment agreements for CEO Yuval Cohen and CFO Sean Moran, effective April 15, 2026.
- CEO Cohen: base salary $673,625, bonus target up to 60%, term through April 15, 2028.
- CFO Moran: base salary $501,273, bonus target up to 40%, term through April 15, 2028.
- CEO severance: 12 months' base salary, COBRA; change-in-control: 24 months, 2x bonus, full vesting.
- CFO severance: 12 months' base salary, COBRA; change-in-control: 18 months, 1x bonus, full vesting.

## SEC filing metadata
- accession: 0001193125-26-159062
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312526159062/0001193125-26-159062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312526159062/crbp-20260415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-159062
- JSON: https://secwatch.observer/filing/0001193125-26-159062.json
- Plain text: https://secwatch.observer/filing/0001193125-26-159062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.